The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells

PLoS Pathogens

Volumn 12, Issue 7, 2016, Pages

  Watson, Alan M ^a   Lam, L K Metthew ^a   Klimstra, William B ^a   Ryman, Kate D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; YELLOW FEVER VACCINE; LIVE VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; T LYMPHOCYTE; VACCINATION; VIRAL PLAQUE ASSAY; VIRUS NEUTRALIZATION; VIRUS VIRULENCE; WEIGHT REDUCTION; YELLOW FEVER; YELLOW FEVER VIRUS; ADOPTIVE TRANSFER; ANIMAL; CD8+ T LYMPHOCYTE; DISEASE MODEL; IMMUNOLOGY;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNITY, HUMORAL; MICE; POLYMERASE CHAIN REACTION; VACCINES, ATTENUATED; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84982980835     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005786     Document Type: Article

References (82)

1. Theiler M, Smith HH, The Use of Yellow Fever Virus Modified by in Vitro Cultivation for Human Immunization. J Exp Med. 1937;65: 787–800. 19870634
2. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11: 622–632. doi: 10.1016/S1473-3099(11)70147-521798462
3. Vaccines and vaccination against yellow fever. WHO position paper—June 2013. Wkly Epidemiol Rec. 2013;88: 269–283. 23909008
4. Barrett ADT, Teuwen DE, Yellow fever vaccine—how does it work and why do rare cases of serious adverse events take place?Curr Opin Immunol. 2009;21: 308–313. doi: 10.1016/j.coi.2009.05.01819520559
5. Gardner CL, Ryman KD, Yellow fever: a reemerging threat. Clin Lab Med. 2010;30: 237–260. doi: 10.1016/j.cll.2010.01.00120513550
6. Gotuzzo E, Yactayo S, Cordova E, Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years. American Journal of Tropical Medicine and Hygiene. 2013;89: 434–444. doi: 10.4269/ajtmh.13-026424006295
7. WHO | Yellow fever vaccination booster not needed [Internet]. [cited 11 Feb 2016]. Available: http://www.who.int/mediacentre/news/releases/2013/yellow_fever_20130517/en/
8. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10: 116–125. doi: 10.1038/ni.168819029902
9. Niedrig M, Lademann M, Emmerich P, Lafrenz M, Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health. 1999;4: 867–871. 10632996
10. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59: 895–900. 6978196
11. Mason RA, Tauraso NM, Spertzel RO, Ginn RK, Yellow Fever Vaccine: Direct Challenge of Monkeys Given Graded Doses of 17D Vaccine. Appl Microbiol. 1973;25: 539–544. 4633476
12. Bugher JC, The Demonstration of Yellow Fever Antibodies in Animal Sera by the Intracerebral Protection Test in Mice. Am J Trop Med Hyg. 1940;s1-20: 809–841.
13. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L’age-Stehr J, Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998;56: 159–167. 9746073
14. Co MDT, Terajima M, Cruz J, Ennis FA, Rothman AL, Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology. 2002;293: 151–163. doi: 10.1006/viro.2001.125511853408
15. Co MDT, Kilpatrick ED, Rothman AL, Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology. 2009;128: e718–e727. doi: 10.1111/j.1365-2567.2009.03070.x19740333
16. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183: 7919–7930. doi: 10.4049/jimmunol.080390319933869
17. Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M, et al. Temporal Dynamics of the Primary Human T Cell Response to Yellow Fever Virus 17D As It Matures from an Effector- to a Memory-Type Response. J Immunol. 2013; doi: 10.4049/jimmunol.1202234
18. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28: 710–722. doi: 10.1016/j.immuni.2008.02.02018468462
19. Akondy RS, Johnson PLF, Nakaya HI, Edupuganti S, Mulligan MJ, Lawson B, et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proceedings of the National Academy of Sciences. 2015;112: 3050–3055. doi: 10.1073/pnas.1500475112
20. James EA, LaFond RE, Gates TJ, Mai DT, Malhotra U, Kwok WW, Yellow Fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and non-structural proteins. Journal of Virology. 2013; doi: 10.1128/JVI.01160-13
21. Monath TP, Vasconcelos PFC, Yellow fever. Journal of Clinical Virology. 2015;64: 160–173. doi: 10.1016/j.jcv.2014.08.03025453327
22. ter Meulen J, Sakho M, Koulemou K, Magassouba N, Bah A, Preiser W, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis. 2004;190: 1821–1827. doi: 10.1086/42501615499539
23. Quaresma JAS, Barros VLRS, Pagliari C, Fernandes ER, Guedes F, Takakura CFH, et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology. 2006;345: 22–30. doi: 10.1016/j.virol.2005.09.05816278000
24. Quaresma JAS, Barros VLRS, Pagliari C, Fernandes ER, Andrade HF, JrVasconcelos PFC, et al. Hepatocyte lesions and cellular immune response in yellow fever infection. Trans R Soc Trop Med Hyg. 2007;101: 161–168. doi: 10.1016/j.trstmh.2006.02.01916872652
25. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. Journal of Experimental Medicine. 2008;205: 3119–3131. doi: 10.1084/jem.2008229219047440
26. Wrammert J, Miller J, Akondy R, Ahmed R, Human immune memory to yellow fever and smallpox vaccination. J Clin Immunol. 2009;29: 151–157. doi: 10.1007/s10875-008-9267-319052852
27. Engelmann F, Josset L, Girke T, Park B, Barron A, Dewane J, Geisbert T, et al. Pathophysiologic and Transcriptomic Analyses of Viscerotropic Yellow Fever in a Rhesus Macaque Model. PLoS Neglected Tropical Diseases. 2014;8: e3295. doi: 10.1371/journal.pntd.000329525412185
28. Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB, Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg. 1981;30: 431–443. 7235133
29. Barrett ADT, Gould EA, Comparison of neurovirulence of different strains of yellow fever virus in mice. Journal of general virology. 1986;67: 631–637. 3958694
30. Meier KC, Gardner CL, Khoretonenko MV, Klimstra WB, Ryman KD, A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 2009;5: e1000614. doi: 10.1371/journal.ppat.100061419816561
31. Vandermost R, Harrington L, Giuggio V, Mahar P, Ahmed R, Yellow Fever Virus 17D Envelope and NS3 Proteins Are Major Targets of the Antiviral T Cell Response in Mice. Virology. 2002;296: 117–124. doi: 10.1006/viro.2002.143212036323
32. Bassi MR, Kongsgaard M, Steffensen MA, Fenger C, Rasmussen M, Skjodt K, et al. CD8+ T Cells Complement Antibodies in Protecting against Yellow Fever Virus. The Journal of Immunology. 2015;194: 1141–1153. doi: 10.4049/jimmunol.140260525539816
33. Quaresma JAS, Duarte MIS, Vasconcelos PFC, Midzonal lesions in yellow fever: a specific pattern of liver injury caused by direct virus action and in situ inflammatory response. Med Hypotheses. 2006;67: 618–621. doi: 10.1016/j.mehy.2006.01.06016650626
34. Pinto MR, Filipe AR, Arbovirus studies in Luanda, Angola. Bull World Health Organ. 1973;49: 31–35. 4545154
35. Mutebi JP, Wang H, Li L, Bryant JE, Barrett AD, Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J Virol. 2001;75: 6999–7008. doi: 10.1128/JVI.75.15.6999-7008.200111435580
36. von Lindern JJ, Aroner S, Barrett ND, Wicker JA, Davis CT, Barrett ADT, Genome analysis and phylogenetic relationships between east, central and west African isolates of Yellow fever virus. J Gen Virol. 2006;87: 895–907. doi: 10.1099/vir.0.81236-016528039
37. Belsher JL, Gay P, Brinton M, DellaValla J, Ridenour R, Lanciotti R, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine. 2007;25: 8480–8485. doi: 10.1016/j.vaccine.2007.08.06118023511
38. McGee CE, Lewis MG, Claire MS, Wagner W, Lang J, Guy B, et al. Recombinant Chimeric Virus with Wild-Type Dengue 4 Virus Premembrane and Envelope and Virulent Yellow Fever Virus Asibi Backbone Sequences Is Dramatically Attenuated in Nonhuman Primates. The Journal of Infectious Diseases. 2008;197: 693–697. doi: 10.1086/52732918266603
39. Pfeffer K, Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine & Growth Factor Reviews. 2003;14: 185–191. doi: 10.1016/S1359-6101(03)00022-4
40. Schroder K, Hertzog PJ, Ravasi T, Hume DA, Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75: 163–189. doi: 10.1189/jlb.060325214525967
41. Trinchieri G, Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3: 133–146. doi: 10.1038/nri100112563297
42. Malek TR, The Biology of Interleukin-2. Annual Review of Immunology. 2008;26: 453–479. doi: 10.1146/annurev.immunol.26.021607.09035718062768
43. Takatsu K, Interleukin 5 and B cell differentiation. Cytokine & Growth Factor Reviews. 1998;9: 25–35. doi: 10.1016/S1359-6101(97)00034-8
44. Monath TP, Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol. 1971;93: 122–129. 5101137
45. Kay A, Chen LH, Sisti M, Monath TP, Yellow Fever Vaccine Seroconversion in Travelers. Am J Trop Med Hyg. 2011;85: 748–749. doi: 10.4269/ajtmh.2011.11-036321976582
46. Rai D, Pham N-LL, Harty JT, Badovinac VP, Tracking the total CD8 T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts. J Immunol. 2009;183: 7672–7681. doi: 10.4049/jimmunol.090287419933864
47. McDermott DS, Varga SM, Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think. J Immunol. 2011;187: 5568–5576. doi: 10.4049/jimmunol.110210422043009
48. Schmidt NW, Butler NS, Badovinac VP, Harty JT, Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog. 2010;6: e1000998. doi: 10.1371/journal.ppat.100099820657824
49. Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, Tygrett LT, et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol. 2012;13: 188–195. doi: 10.1038/ni.2180
50. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401: 708–712. doi: 10.1038/4438510537110
51. Masopust D, Vezys V, Marzo AL, Lefrançois L, Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001;291: 2413–2417. doi: 10.1126/science.105886711264538
52. Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunology. 2003;4: 225–234. doi: 10.1038/ni88912563257
53. Jameson SC, Masopust D, Diversity in T cell memory: an embarrassment of riches. Immunity. 2009;31: 859–871. doi: 10.1016/j.immuni.2009.11.00720064446
54. Obar JJ, Lefrancois L, Early events governing memory CD8+ T-cell differentiation. International Immunology. 2010;22: 619–625. doi: 10.1093/intimm/dxq05320504887
55. Cui W, Kaech SM, Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev. 2010;236: 151–166. doi: 10.1111/j.1600-065X.2010.00926.x20636815
56. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. Journal of Immunological Methods. 2003;281: 65–78. doi: 10.1016/S0022-1759(03)00265-514580882
57. Tatum AM, Watson AM, Schell TD, Direct Presentation Regulates the Magnitude of the CD8+ T Cell Response to Cell-Associated Antigen through Prolonged T Cell Proliferation. J Immunol. 2010;185: 2763–2772. doi: 10.4049/jimmunol.090392020660711
58. Doblas A, Domingo C, Bae HG, Bohórquez CL, de Ory F, Niedrig M, et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. Journal of Clinical Virology. 2006;36: 156–158. doi: 10.1016/j.jcv.2006.02.00516597510
59. Rothman AL, Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol. 2010;338: 83–98. doi: 10.1007/978-3-642-02215-9_719802580
60. Kohler S, Bethke N, Böthe M, Sommerick S, Frentsch M, Romagnani C, et al. The early cellular signatures of protective immunity induced by live viral vaccination. European Journal of Immunology. 2012;42: 2363–2373. doi: 10.1002/eji.20114230622733156
61. Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC)Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59: 1–27.
62. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, et al. A Protective Role for Dengue Virus-Specific CD8+ T Cells. J Immunol. 2009;182: 4865–4873. doi: 10.4049/jimmunol.080197419342665
63. Brien JD, Uhrlaub JL, Nikolich-\vZugich J, Protective capacity and epitope specificity of CD8+ T cells responding to lethal West Nile virus infection. European journal of immunology. 2007;37: 1855–1863. 17559175
64. Shrestha B, Diamond MS, Role of CD8+ T Cells in Control of West Nile Virus Infection. Journal of Virology. 2004;78: 8312–8321. doi: 10.1128/JVI.78.15.8312-8321.200415254203
65. Brien JD, Uhrlaub JL, Nikolich-Žugich J, West Nile Virus-Specific CD4 T Cells Exhibit Direct Antiviral Cytokine Secretion and Cytotoxicity and Are Sufficient for Antiviral Protection. J Immunol. 2008;181: 8568–8575. 19050276
66. Gagnon SJ, Ennis FA, Rothman AL, Bystander target cell lysis and cytokine production by dengue virus-specific human CD4+ cytotoxic T-lymphocyte clones. Journal of virology. 1999;73: 3623–3629. 10196254
67. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF, Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to Stimulate Clonal Expansion and Differentiation. J Immunol. 2005;174: 4465–4469. 15814665
68. Haring JS, Badovinac VP, Harty JT, Inflaming the CD8+ T Cell Response. Immunity. 2006;25: 19–29. doi: 10.1016/j.immuni.2006.07.00116860754
69. Thompson LJ, Kolumam GA, Thomas S, Murali-Krishna K, Innate Inflammatory Signals Induced by Various Pathogens Differentially Dictate the IFN-I Dependence of CD8 T Cells for Clonal Expansion and Memory Formation. J Immunol. 2006;177: 1746–1754. 16849484
70. Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF, Programming for CD8 T Cell Memory Development Requires IL-12 or Type I IFN. J Immunol. 2009;182: 2786–2794. doi: 10.4049/jimmunol.080348419234173
71. Havenar-Daughton C, Kolumam GA, Murali-Krishna K, Cutting Edge: The Direct Action of Type I IFN on CD4 T Cells Is Critical for Sustaining Clonal Expansion in Response to a Viral but Not a Bacterial Infection. J Immunol. 2006;176: 3315–3319. 16517698
72. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K, Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202: 637–650. doi: 10.1084/jem.2005082116129706
73. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. The Journal of Experimental Medicine. 2006;203: 413–424. doi: 10.1084/jem.2005172016461338
74. Deauvieau F, Sanchez V, Balas C, Kennel A, De Montfort A, Lang J, et al. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1–4. The American journal of tropical medicine and hygiene. 2007;76: 144–154. 17255244
75. Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, Barvir D, et al. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. Journal of General Virology. 2007;88: 148–156. doi: 10.1099/vir.0.82272-017170447
76. Gandini M, Reis SRNI, Torrentes-Carvalho A, Azeredo EL, Freire M da S, Galler R, et al. Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-α and IFN-α profiles. Memórias do Instituto Oswaldo Cruz. 2011;106: 594–605. 21894381
77. Mandl JN, Akondy R, Lawson B, Kozyr N, Staprans SI, Ahmed R, et al. Distinctive TLR7 Signaling, Type I IFN Production, and Attenuated Innate and Adaptive Immune Responses to Yellow Fever Virus in a Primate Reservoir Host. The Journal of Immunology. 2011;186: 6406–6416. doi: 10.4049/jimmunol.100119121515797
78. Bruni D, Chazal M, Sinigaglia L, Chauveau L, Schwartz O, Desprès P, et al. Viral entry route determines how human plasmacytoid dendritic cells produce type I interferons. Science signaling. 2015;8: ra25–ra25. doi: 10.1126/scisignal.aaa155225737587
79. Watson AM, Mylin LM, Thompson MM, Schell TD, Modification of a Tumor Antigen Determinant To Improve Peptide/MHC Stability Is Associated with Increased Immunogenicity and Cross-Priming a Larger Fraction of CD8+T Cells. J Immunol. 2012; doi: 10.4049/jimmunol.1102221
80. Tevethia SS, Greenfield RS, Flyer DC, Tevethia MJ, SV40 transplantation antigen: relationship to SV40-specific proteins. Cold Spring Harb Symp Quant Biol. 1980;44Pt 1,: 235–242.
81. Bredenbeek PJ, Kooi EA, Lindenbach B, Huijkman N, Rice CM, Spaan WJM, A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol. 2003;84: 1261–1268. doi: 10.1099/vir.0.18860-012692292
82. Lippolis JD, Mylin LM, Simmons DT, Tevethia SS, Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. J Virol. 1995;69: 3134–3146. 7535867